Ascentage Pharma Group International logo

Ascentage Pharma Group International

AAPG | NASDAQ
Chart Builder DCF Calculator
$13.29
-$1.33 (-9.10%)
At close: Nov 16, 2026, 4:00 PM ET
$13.40
+$0.11 (+0.83%)
After-hours: Nov 16, 2026, 7:30 PM ET
-9.10%

Rating

Updated: Nov 16, 2026
47.8
+0.2 pts
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #333/1021 (Top 33%)

Key Statistics

Market Data

Market Cap $1.24B
1D Range
13.26 13.90
52W Range
13.26 32.88

Valuation (TTM)

PE -5.96
PB 15.06
EV/EBITDA -6.60

Valuation (NTM)

Forward PE 8.28
Forward PEG 0.09
Price Target $45.00
Loading financial charts...

Profile

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic ...

Sector Healthcare
Industry Biotechnology
Employees 767
IPO Date Jan 24, 2025
Fiscal Year January - December

Latest News

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

1 day ago · globenewswire.com

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

12 days ago · globenewswire.com

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

14 days ago · globenewswire.com

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

27 days ago · globenewswire.com

Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Ascentage Pharma Stock Could More Than Double: Analyst

1 month ago · benzinga.com

Ascentage Pharma Stock Could More Than Double: Analyst
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

1 month ago · marketbeat.com

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

1 month ago · marketbeat.com

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Ascentage Pharma Group International H1 Earnings Call Highlights

3 months ago · marketbeat.com

Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

3 months ago · globenewswire.com

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Earnings

Next Earnings
Mar 31, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$45.00
Upside
+238.60%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.